FDA Approves Tudriqev for Advanced Melanoma: How Home Health Care Supports Recovery

The FDA has approved Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for certain adults with unresectable advanced cutaneous melanoma whose cancer progressed after PD-1 therapy. This new advanced melanoma treatment offers another option for patients facing treatment-resistant disease.

What Is Tudriqev?

Tudriqev is an oncolytic viral therapy designed to target cancer cells and stimulate an immune response. Treatment involves injections directly into tumors along with nivolumab. Patients should discuss potential benefits, side effects, and safety precautions with their oncology team.

Supporting Recovery at Home

Cancer treatment can involve fatigue, pain, weakness, medication needs, and frequent medical appointments. For eligible patients, home health care during cancer treatment can provide skilled support between oncology visits.

OCTIHEALTH helps patients and families coordinate home health care with physicians. Depending on the patient's individualized plan of care, services may include skilled nursing, medication education, monitoring for changes in condition, physical therapy, occupational therapy, home health aide services, and medical social work.

Medicare may cover qualifying home health services when eligibility and coverage requirements are met.

OCTIHEALTH proudly provides home health care in the Chicago suburbs, helping patients remain safely at home while receiving professional support during recovery.

Call OCTIHEALTH at (847) 305-3070 to learn more about home health services during cancer treatment.

This article is for educational purposes and is not medical advice. Consult your oncology team about treatment decisions.

References: FDA: Cellular, Tissue, and Gene Therapies Advisory CommitteeMedicare: Home Health Services